Cannabis Compounds Show Promise Against Cancer and Viral Disease—But the Evidence Is Still Largely Preclinical
Cannabis Compounds Show Promise Against Cancer and Viral Disease, But the Evidence Is Still Largely Preclinical
A 2024 narrative review surveys the breadth of cannabis-derived compound research across cancer, viral disease, and neurological conditions, revealing that while two products hold regulatory approval for epilepsy and MS spasticity, the vast majority of anticancer and antiviral claims rest on preclinical data that cannot yet support clinical recommendations.
Why This Matters
The global market for cannabis-derived products reached an estimated $2.6 billion in 2022, and patient interest in cannabinoid therapies continues to outpace the clinical evidence supporting most proposed uses. Clinicians face mounting pressure to advise patients who arrive with optimistic headlines about cannabis and cancer or COVID-19 prevention. Understanding where the evidence is genuinely strong and where it remains speculative is essential for responsible practice. This review arrives at a moment when the gap between commercial momentum and scientific rigor demands careful navigation.
Clinical Summary
Cannabis sativa L. produces over 125 cannabinoids along with terpenes, flavonoids, and other secondary metabolites that have documented biological activity in laboratory settings. A 2024 narrative review by a researcher at the University of Lodz, published in the International Journal of Molecular Sciences, synthesizes approximately 157 sources across cancer, viral disease, neurological disorders, and autoimmune conditions. The review correctly identifies that only two cannabis-derived products hold regulatory approval: Epidiolex, an oral CBD formulation approved by the FDA for certain forms of epilepsy, and Sativex, an oromucosal THC and CBD spray used in some jurisdictions for multiple sclerosis spasticity. Both are supported by randomized clinical trial data. The mechanistic rationale for broader applications centers on cannabinoid modulation of the endocannabinoid system, CB1 and CB2 receptor signaling, and downstream effects on apoptosis, autophagy, inflammation, and immune regulation.
For cancer, the review highlights in vitro and animal model data showing cannabinoid-induced apoptosis, antiproliferative effects, and tumor regression, with a phase II clinical trial of a THC and CBD combination alongside temozolomide in glioblastoma described as “very promising.” For antiviral applications, the review cites preclinical evidence of SARS-CoV-2 replication inhibition and a large observational study of 93,565 individuals associating prior CBD use with lower COVID-19 incidence. However, observational association does not establish causation, and the antiviral claims remain methodologically insufficient for clinical application. The review’s primary limitation is its narrative, non-systematic design: it lacks PRISMA reporting, formal inclusion and exclusion criteria, and critical appraisal of individual study quality. The author acknowledges that rigorous clinical validation is needed before therapeutic conclusions can be drawn for nearly all applications beyond epilepsy and MS spasticity.
Dr. Caplan’s Take
This review does something useful: it maps the landscape of cannabinoid research across a wide range of diseases. That breadth, however, is also its weakness. When preclinical cell-line data and FDA-approved clinical trial evidence appear in the same narrative without consistent quality grading, readers can easily conflate what is proven with what is merely plausible. The patients I see who ask about cannabis for cancer or viral illness are often responding to exactly this kind of conflation in popular reporting. An honest answer requires separating the two or three areas where we have real clinical confidence from the many where we have only laboratory hypotheses.
In practice, I discuss Epidiolex and Sativex as evidence-based options for their approved indications. For patients interested in cannabinoids for cancer or other conditions covered in this review, I explain that the preclinical findings are genuinely interesting but that we do not yet have the human trial data to recommend these approaches as treatments. I focus on symptom management, where cannabinoids have a more established role, and I monitor for drug interactions, particularly in patients on antiepileptic or immunosuppressive regimens. We should follow this science closely, but we should not get ahead of it.
Clinical Perspective
This review sits early in the research arc for most of the conditions it covers. For epilepsy and MS spasticity, the evidence has matured through randomized controlled trials to regulatory approval, and clinicians can recommend Epidiolex and Sativex with reasonable confidence within their approved indications. For anticancer applications, the glioblastoma combination trial with temozolomide represents a meaningful step, but it remains early-phase and cannot yet be generalized. For antiviral applications, including COVID-19, the evidence is almost entirely preclinical or observational, and clinicians should not frame cannabinoids as preventive or therapeutic for SARS-CoV-2 based on current data. Claims about lupus, type 1 diabetes, and Alzheimer’s disease are similarly hypothesis-generating at best.
Pharmacological considerations are important across this landscape. CBD is a potent inhibitor of several cytochrome P450 enzymes, including CYP3A4 and CYP2C19, creating meaningful interaction risks with chemotherapy agents, anticoagulants, and immunosuppressants. THC carries psychoactive and cardiovascular effects that require monitoring, particularly in older or medically complex patients. Hepatotoxicity has been documented with high-dose CBD in the Epidiolex trials, necessitating liver function monitoring. For clinicians seeing patients who ask about cannabis for conditions beyond approved indications, the most actionable step right now is to document the conversation, clarify what the evidence does and does not support, and screen for potential drug interactions before any cannabinoid use begins.
Study at a Glance
- Study Type
- Narrative review (non-systematic)
- Population
- Preclinical models (cell lines, animal studies) and limited human clinical populations across cancer, viral disease, epilepsy, MS, and autoimmune conditions
- Intervention
- Cannabis-derived compounds including CBD, THC, minor cannabinoids, terpenes, and flavonoids
- Comparator
- Not applicable (narrative synthesis)
- Primary Outcomes
- Anticancer mechanisms (apoptosis, autophagy, antiproliferation), antiviral activity, neuroprotective and immunomodulatory effects
- Sample Size
- 157 articles included from approximately 250 initially identified
- Journal
- International Journal of Molecular Sciences (MDPI)
- Year
- 2024
- DOI or PMID
- Not provided in source material
- Funding Source
- Not specified
What Kind of Evidence Is This
This is a single-author narrative review published in an open-access peer-reviewed journal. Narrative reviews occupy a lower tier in the evidence hierarchy compared to systematic reviews and meta-analyses because they lack pre-specified search protocols, formal inclusion and exclusion criteria, and standardized quality appraisal of included studies. The most important inference constraint this imposes is that the selection and emphasis of cited evidence may reflect the author’s interpretive lens rather than a transparent, reproducible assessment of the full literature, making the review useful for hypothesis generation but unreliable as a basis for clinical decision-making.
How This Fits With the Broader Literature
The review’s strongest claims align with well-established regulatory evidence. The efficacy of Epidiolex for Dravet and Lennox-Gastaut syndromes is supported by multiple phase III randomized controlled trials, including the work of Devinsky and colleagues published in the New England Journal of Medicine. The glioblastoma findings echo the GW Pharmaceuticals phase II trial (NCT01812616), which showed a trend toward improved survival with THC and CBD combined with temozolomide, though the trial was small and preliminary.
Where this review extends the literature is in its attempt to consolidate antiviral, autoimmune, and neuroprotective claims under a single framework. However, similar narrative syntheses have been published in recent years, and the COVID-19-related claims specifically have been met with skepticism in systematic assessments. The large observational study of CBD and SARS-CoV-2 incidence, while frequently cited, has not been independently replicated with designs capable of controlling for the substantial confounders inherent in self-selected supplement use.
Common Misreadings
The most likely overinterpretation of this review is treating its survey of preclinical anticancer and antiviral findings as evidence that cannabinoids are effective treatments for cancer or COVID-19 in humans. The review itself uses language such as “very promising” that, when extracted from context, can fuel headlines suggesting clinical utility that does not yet exist. In vitro apoptosis in a cancer cell line does not translate directly to tumor regression in patients. Similarly, association between CBD use and lower SARS-CoV-2 incidence in an observational cohort does not demonstrate that CBD prevents or treats COVID-19. Readers and clinicians should note that only two of the many applications discussed carry regulatory approval based on randomized trial evidence.
Bottom Line
This narrative review provides a broad survey of cannabinoid research across multiple disease areas, confirming that Epidiolex and Sativex remain the only cannabis-derived medicines with robust clinical trial support. The anticancer and antiviral findings are biologically interesting but overwhelmingly preclinical. This review is best understood as a map of research directions, not a guide to clinical action. Until well-designed human trials validate the most promising preclinical signals, clinicians should confine evidence-based cannabinoid recommendations to approved indications.
References
- Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020. DOI: 10.1056/NEJMoa1611618
- Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888-1897. DOI: 10.1056/NEJMoa1714631
- GW Pharmaceuticals. A phase 1b/2a study to investigate the safety of Sativex in combination with dose-intense temozolomide in patients with recurrent glioblastoma. ClinicalTrials.gov Identifier: NCT01812616.
- Nguyen LC, Yang D, Nicolaescu V, et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022;8(8):eabi6110. DOI: 10.1126/sciadv.abi6110
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. DOI: 10.1001/jama.2015.6358
- Source review published in International Journal of Molecular Sciences (MDPI), 2024. University of Lodz, Poland. Specific DOI not provided in source material.
Have thoughts on this? Share it:
